From L-R: Arda Therapeutics chief technology officer Remi-Martin Laberge, CEO Adam Freund and CSO Scott Turner
October 8, 2024 07:30 AM EDTUpdated October 9, 05:32 PM
Financing
Startups

Ex­clu­sive: Lil­ly backs a16z-fund­ed Ar­da Ther­a­peu­tic­s' $43M Se­ries A to take AD­Cs in­to fi­bro­sis

Kyle LaHucik

Senior Reporter

A three-year-old start­up based on decades of re­search in cell de­ple­tion is bet­ting that some of the hottest tools in on­col­o­gy may work even bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times